174 related articles for article (PubMed ID: 1384801)
41. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
[TBL] [Abstract][Full Text] [Related]
42. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
43. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
[TBL] [Abstract][Full Text] [Related]
44. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents.
Newton DL; Hansen HJ; Liu H; Ruby D; Iordanov MS; Magun BE; Goldenberg DM; Rybak SM
Crit Rev Oncol Hematol; 2001; 39(1-2):79-86. PubMed ID: 11418304
[TBL] [Abstract][Full Text] [Related]
45. The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies.
Li JL; Shen GL; Ghetie MA; May RD; Till M; Ghetie V; Uhr JW; Janossy G; Thorpe PE; Amlot P
Cell Immunol; 1989 Jan; 118(1):85-99. PubMed ID: 2463099
[TBL] [Abstract][Full Text] [Related]
46. The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life.
Pop LM; Liu X; Ghetie V; Vitetta ES
Int Immunopharmacol; 2005 Jul; 5(7-8):1279-90. PubMed ID: 15914332
[TBL] [Abstract][Full Text] [Related]
47. A comparison of the anti-tumor effects of a chimeric versus murine anti-CD19 immunotoxins on human B cell lymphoma and Pre-B acute lymphoblastic leukemia cell lines.
Tsai LK; Pop LM; Liu X; Vitetta ES
Toxins (Basel); 2011 Apr; 3(4):409-19. PubMed ID: 22069716
[TBL] [Abstract][Full Text] [Related]
48. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
[TBL] [Abstract][Full Text] [Related]
49. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
[TBL] [Abstract][Full Text] [Related]
50. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies.
Keppler-Hafkemeyer A; Kreitman RJ; Pastan I
Int J Cancer; 2000 Jul; 87(1):86-94. PubMed ID: 10861457
[TBL] [Abstract][Full Text] [Related]
51. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
[TBL] [Abstract][Full Text] [Related]
52. Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells.
Mansfield E; Chiron MF; Amlot P; Pastan I; FitzGerald DJ
Biochem Soc Trans; 1997 May; 25(2):709-14. PubMed ID: 9191188
[No Abstract] [Full Text] [Related]
53. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.
Liu XY; Pop LM; Tsai L; Pop IV; Vitetta ES
Int J Cancer; 2011 Jul; 129(2):497-506. PubMed ID: 20878959
[TBL] [Abstract][Full Text] [Related]
54. Selective killing of normal and neoplastic human B cells with anti-CD19- and anti-CD22-ricin A chain immunotoxins.
May RD; Vitetta ES; Moldenhauer G; Dörken B
Cancer Drug Deliv; 1986; 3(4):261-72. PubMed ID: 2436739
[TBL] [Abstract][Full Text] [Related]
55. A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.
Schindler J; Gajavelli S; Ravandi F; Shen Y; Parekh S; Braunchweig I; Barta S; Ghetie V; Vitetta E; Verma A
Br J Haematol; 2011 Aug; 154(4):471-6. PubMed ID: 21732928
[TBL] [Abstract][Full Text] [Related]
56. Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA.
Newton DL; Ryback SM
Expert Opin Biol Ther; 2001 Nov; 1(6):995-1003. PubMed ID: 11728231
[TBL] [Abstract][Full Text] [Related]
57. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.
French RR; Penney CA; Browning AC; Stirpe F; George AJ; Glennie MJ
Br J Cancer; 1995 May; 71(5):986-94. PubMed ID: 7734325
[TBL] [Abstract][Full Text] [Related]
58. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
Vuist WM; v Buitenen F; de Rie MA; Hekman A; Rümke P; Melief CJ
Cancer Res; 1989 Jul; 49(14):3783-8. PubMed ID: 2472198
[TBL] [Abstract][Full Text] [Related]
59. Cytotoxic potency of CD22-ricin A depends on intracellular routing rather than on the number of internalized molecules.
van Horssen PJ; van Oosterhout YV; de Witte T; Preijers FW
Scand J Immunol; 1995 Jun; 41(6):563-9. PubMed ID: 7770726
[TBL] [Abstract][Full Text] [Related]
60. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
